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bstract
Health-economic modelling is useful for assessing the clinical requirements and impact of new vaccines. In this study, we estimate the
mpact of potential vaccination for respiratory syncytial virus (RSV) of infants in the Netherlands. A decision analysis model was employed
sing seasonal data from a cohort of children (1996–1997 through 1999–2000) to assess hospitalisation, costs and impact of vaccination.
early, an estimated 3670 infants are hospitalised with RSV-infection in the Netherlands, vaccination protecting infants from 3 months of
ife onwards could prevent approximately 1000–3000 hospitalisations, depending on the effectiveness of the potential vaccine. Additionally,
accination could prevent a major share of RSV-related costs. Comparison of the calculated break-even prices with the average price of
ecently introduced vaccines indicates that pricing for a potential RSV-vaccine most likely allows for only a single dose vaccination or several
oses at a relatively low price per dose in order to achieve cost savings. However, if evidence on relevant RSV-related mortality would become
vailable, higher pricing would be justified, while still remaining below accepted thresholds for cost-effectiveness.
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. Introduction
Human respiratory syncytial virus (RSV) infection is
he most important cause of viral respiratory tract infec-
ion in infants. RSV causes upper and lower respiratory
ract infection and can lead to pneumonia or bronchioli-
is [1,2]. It is estimated that every child at the age of
wo has been infected at least once with RSV [3]. The
pidemiology of RSV in northern regions with temperate
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oi:10.1016/j.vaccine.2007.07.006limates is characterized by seasonality, with almost all
ases occurring between October and April [1,2]. Severe
SV-infection with hospitalisation occurs in approximately
.5–2% of the infected infants [3]. Prematurely born infants
nd infants with congenital heart disease (CHD) and broncho-
ulmonary disease (BPD) are at increased risk for severe
SV-disease. The American Academy of Pediatrics (AAP)
ecommends RSV-prophylaxis during the RSV-season for
nfants with lung and heart diseases and those born pre-
aturely [4]. Primary prophylaxis may be achieved by
dministering either palivizumab or RSV-immunoglobulin.
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ide these known high-risk groups, implying that despite
rophylaxis RSV still remains a significant source for
orbidity.
Although mortality may be relatively low for RSV-
nfection, the impact on quality of life of both the child
nd its parents is potentially large [5]. Also, due to the
igh incidence of RSV-infection in infants, costs and bur-
en of illness for society may be substantial, especially when
he costly treatment with palivizumab or immunoglobulin
s secondary prophylaxis to prevent severe RSV-disease is
aken into account [6]. Next to infections of the respiratory
ract, RSV infection is also suspected to be a major cause
f otitis media, which is one of the most frequently occur-
ing diseases in childhood [7]. RSV-infection is additionally
ssociated with recurrent episodes of wheezing [8], which
ay lead to increased costs of care and a reduced quality of
ife. One further issue concerns the identification of RSV-
nfection. In particular, the infection is often conceived and
lassified as influenza, leading to potentially large underes-
imation of the real burden of RSV [9]. On the other hand,
he recently discovered human metapneumovirus (hMPV)
auses respiratory tract infections in infants and children
ith symptoms very similar to those of RSV-infection and
ence hMPV-infections may be occasionally mistaken for
SV, thus causing a slight overestimate of the RSV incidence
10,11].
In the light of burden of disease, the potential for under-
iagnosis, and the low efficacy of the possible prophylactic
egimens, ideally a vaccine should be available that actively
rotects infants and children at risk and reduces transmission
f the virus. Until now, however, there is no effective vac-
ine against RSV-infection available. Yet, some early phase
rials are going on. A major setback in the development
f RSV-vaccines has been the unfortunate experience with
ormalin-inactivated RSV-vaccine formulations (FI-RSV) in
he 1960s. This FI-RSV was administered to infants and chil-
ren in the USA. Upon subsequent exposure to live virus in
he winter season of 1966–67, several of these vaccinated
hildren developed enhanced disease and two vaccinated
hildren even died as a result of RSV-infection. Despite
umerous studies into the basis of vaccine-induced severe
SV-disease, it is still not entirely clear what the immunolog-
cal correlates of the observed enhanced RSV-pathology are.
urrently, there are two types of candidate vaccines in clin-
cal evaluation: live-attenuated for vaccination of primarily
SV-seronegative young infants, and inactivated subunit for-
ulations for vaccination of the elderly and RSV-seropositive
hildren at risk for severe RSV-disease and pregnant women
12–14]. A difficulty but – given the epidemiology – yet
mportant requirement for a successful vaccine against RSV-
nfection in children would be the ability of such a vaccine
o safely induce protective efficacy at a very early age.Health-economic modelling can be used to assess the
mpact of future preventive and therapeutic strategies and to
stimate threshold values for important characteristics such





ty to induce protective immunity and reduce transmission of
he virus, are at least partly determined by the exact vac-
ine formulation (inclusive the use of an adjuvant) and the
oute of vaccine administration. The use of an appropriate
odel may even allow us to estimate the exact optimal tim-
ng of vaccination in close conjunction with these specific
accine characteristics. The results of the model may thus
ontribute to decisions regarding timing of vaccination and
he associated price of the vaccine [15].
Outputs of a health-economic model are important
or policy makers of national immunization schedules
o provide epidemiological output on morbidity averted,
ost-effectiveness output and budget impact, all necessary
omponents in a planning of future additions to National
mmunization Programs. Furthermore, the model may pro-
uce break-even vaccine prices where financial benefits
utweigh the vaccine costs, providing additional informa-
ion on the expected willingness to pay for the vaccine and
ence on the expected returns on investment and feasibility of
he efforts. This information may in turn influence decisions
n the funding of RSV-vaccine research programs. Summa-
izing, knowledge of the impact of vaccine parameters such
s price and minimum efficacy may crucially contribute to
ecisions regarding vaccine development and future use of
he vaccine in National Immunization Programs.
In this paper, a health-economic model is presented sim-
lating RSV-vaccination of infants in The Netherlands. In
articular, scenarios for various values of effectiveness and
iming of potential vaccination are made, seasonal patterns
re investigated and break-even costs for vaccination are ana-
yzed. The model allows calculation of cost-effectiveness per
ife-year gained, however the scarcely available Dutch data
ndicate no case fatalities for RSV in Dutch infants. In the
bsence of Dutch data on mortality for RSV-infected chil-
ren, in the discussion part of this paper some further tentative
nalysis is performed on USA-data on mortality. This allows
he specification of acceptable costs of the potential vaccine
ith regard to thresholds for the cost per life-year gained that
ave recently been suggested for the Netherlands. As such,
his paper illustrates the use of pharmacoeconomic models
t an early stage of drug or vaccine development, whereas
he majority of papers published in the field yet relate to




We developed a health-economic model for RSV-
accination directed at children without BPD (it was assumed
hat BPD-infants would be vaccinated without any discus-
ion if an RSV-vaccine became available given the high level
f risk for these infants). The costs and effects of RSV-
accination of non-BPD infants were assessed in a cohort

















































Characteristics of the cohort of children hospitalised with proven RSV-
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odel, following a birth cohort twice: once without vaccina-
ion and once with vaccination at assumed plausible values
or effectiveness and period of protection. The size of the
irth cohort in the Netherlands is approximately 200,000.
his cohort is subject to probabilities for hospitalisation due
o RSV within a cycle length of the model of 1 month.
o, the model is evaluated on a monthly basis; i.e. during
ny month the cohort faces specific probabilities for RSV-
ospitalisation. Such transition probabilities and costs of
ospitalisation were derived from a retrospective population-
ased study, conducted in the South-west of the Netherlands
16,17]. The time horizon of the model was limited to 24
onths (after birth), as it has been found that nearly all
SV-hospitalisations in children occur in this period. The
odel thus effectively limits the duration of protection of
accination to a time period of maximally 24 months after
accination. The net costs were defined as the costs of the vac-
ination programme minus the savings on health-care costs
or severe RSV-infections. Costs of hospitalisation were mod-
lled using a regression model based on the retrospective
opulation based study. Non-hospital costs were derived from
nother source (see below). All costs were expressed in 2003
rice levels.
.2. Retrospective population-based study
In the retrospective population-based study, data on risk
actors and hospital resource use was gathered from all
hildren with an RSV-related hospitalisation in one of the
9 regional hospitals in the South-west of the Netherlands
uring four consecutive RSV-seasons 1996–1997 through
999–2000 [16]. In this region, approximately 47,000 infants
re born annually. Of these cohorts, 3458 were hospi-
alised for RSV during the whole period. Table 1 presents
he patient characteristics. Detailed information for these
atients on level of care, diagnostics and medical interven-
ions was gathered from medical records. Resource use was
ransformed into costs using unit prices including accomo-
ation, overhead, nondisposable equipment, personel and
isposables [16]. Time and equipment needed was esti-
ated through questionnaires among caregivers [16]. In
he end, all RSV-hospitalisations could be labelled with a
ost estimate (price-level 2000; updated for this study to
003).
With these data, a linear regression model was devel-
ped with hospitalisation costs as the outcome. This model
nabled forecasting hospitalisation costs based on risk factors
ncluding gestational age, birth weight and BPD. The regres-
ion model has been extensively described in the literature
y Rietveld et al. [17]. For our study the regression model
or non-BPD infants was used, forecasting hospitalisation1 + exp(7.013 − 0.335 × gender − 0.545




2274 + 1226 × ga1 + 313 × ga2 + 591 × bw1






ith ga1 = gestational age ≤28 weeks; ga2 = gestational
ge from 29 to 34 weeks; bw1 = birth weight ≤2500 g;
w2 = birth weight from 2501 to 3000 g; age = age in months
the term 1/(age + 1) was included to stabilise variance [17]).
his implies that in the model hospital costs vary by age, ges-
iational age and birth weigth: theoretically, from just over
2300 to a maximum of D 6283.
Previously, a subset of the patients in Table 1 (seasons
996–1997 through 1998–1999) was used to estimate the
isk of being hospitalised for RSV, based on population-
ased risk factors [15]. Risk factors considered for non-BPD
nfants were selected from the literature and included the
ame as mentioned above (gestational age, birth weight and
ge) in addition to gender and month of the year (reflecting
easonality of RSV). The following prediction rule for the
onthly RSV-hospitalisation risk was specified for non-BPD
hildren during the RSV-season (October through April; for
ther months the expected number of RSV-hospitalisations1
× bw1 − 0.234 × bw2 − 1.150 × ga1 − 1.042ga2′
aged + 0.207 × age − 0.851 × s
(2)









































































effectiveness was estimated monthly in terms of net costs per
hospitalisation averted.J.M. Bos et al. / Vac
ith ga1 = gestational age ≤28 weeks; ga2′ = from 29 to 32
eeks; ga3 = 33 or 34; ga4 = 35 or 36; bw1 = birth weight
2500 g; bw2 = birth weight from 2501 to 3000 g; age = age
n months;1 aged = 0 if age = 0, aged = 1 otherwise; s reflects
he seasonal factor at −1.40 for October, 0.53 for Novem-
er, 1.36 for December, 0.83 for January, 0.53 for February,
0.22 for March and −1.63 for April. The regression mod-
ls have been validated previousy [16,17]. Overall goodness
f fit of both models was satisfactory, as indicated by
n R2 of 0.85 for the cost model and a non-significant
osmer–Lemeshow test (p = 0.79) for the risk model
16,17].
.3. Cohort model
The resulting regression models were used as input for
he cohort model in which infants born in a specific month
ere followed for 24 months. The model simulates the risk
f children becoming hospitalized due to RSV infection
sing formula (2). For this purpose, the monthly num-
ers of children born in 2003 (maximum: 17,000 in July
nd August; minimum: 15,000 in February; source: Cen-
ral Bureau of Statistics Netherlands) were taken and the
isks estimated from the regression models were used to
ssess the actual number of children hospitalised. It was
ssumed that 99% of the infants were non-BPD children
16,17]. Distributions of gestational age and birth weight of
he monthly birth cohorts were also based on the informa-
ion on the annual birth cohorts followed by Rietveld et al.
16,17].
In the next step of the model, corresponding costs of hos-
italisations were calculated using formula (1). In the model
ospital costs were inflated to reflect 2003 price levels using
ppropriate deflators [18]. Based on a study on societal costs
f RSV-infection in infants in the Netherlands, it was assumed
hat hospital costs reflected 87% of all societal costs related to
severe RSV-episode [19]. In particular, additional costs arise
or GP-visits, home care and work loss of parents [19]. Fur-
hermore, discounting at 4% was applied to costs for children
ged 12 months and over [18].
The model was once evaluated without vaccination; i.e.
he natural course of infections as has been observed in the
tudy by Rietveld et al. [16,17]. Then, the model was eval-
ated assuming a vaccination with a specific effectiveness
chieved (% infections/hospitalisations prevented), a specific
tarting month of such protection (immediately in the first
onth after birth is the earliest theoretical option) and specific
accination costs, i.e. vaccine price plus administration costs
the latter are D 6.2 in the Netherlands [20]). Each combina-
ion of effectiveness and first month of life with protection
orms a specific scenario. Note that effectiveness and starting
onth of protection are specified, we do not specify the exact
oments for vaccination. If, for example, the first month of
1 For premature infants, age was corrected to a duration of pregnancy of
8 weeks [17].
F
(ig. 1. Percentage distribution of RSV-hospitalisations in the Netherlands
source: [16,17]).
rotection is the third month of a child’s life, we implicitly
ssume that vaccination is performed prior to that month (i.e.
n months 1 and 2).
As outcomes in our scenarios two entities were chosen: (i)
reak-even costs of vaccination and (ii) net costs per hospital-
sation averted. Mortality nor life-years gained were included
n the model. In fact, no fatal RSV-infections were observed
n the Dutch retrospective research outlined above[16,17].
lso, impacts in terms of quality of life or the effects on
he occurrence of long term effects (i.e. wheezing) were not
ncluded at this stage of the research.
During the period of analysis, RSV-infection (as is com-
on in Northern climates) followed a highly seasonal pattern,
ith infections occurring between October and April (Fig. 1).
ince risks are also highly depending on age (younger infants
re more susceptible for RSV-infection; Fig. 2), the risk
f becoming hospitalised for RSV and correspondingly the
bsolute efficacy of RSV-vaccination, will depend on the
ate of birth of the infant in relation to the RSV-season (just
rior to the RSV-season or not). As a consequence, the cost-
ffectiveness of RSV-vaccination will shift throughout the
eason. To account for this, we also present the results of the
odel for all months of birth separately; in particular, cost-ig. 2. Cumulative distribution of cases of RSV according to month of life
source: [16,17]).
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Table 2
Number of RSV related hospitalisations averted for a birth-cohort of Dutch infants for a range of vaccine effectiveness and start of protective immunity by
month of life (95% confidence intervals are shown between brackets)
Effectiveness (%) Start protective immunity (month of life)
1 2 3 4 5 6
50 1760 (1010–3010) 1430 (790–2610) 1170 (640–2050) 950 (550–1900) 770 (410–1400) 620 (330–1120)
60 2110 (1090–3750) 1720 (1020–2880) 1400 (790–2320) 1140 (660–2080) 920 (520–1620) 740 (430–1320)


























































180 2820 (1610–4830) 2300 (1360–3860) 1870
90 3170 (1810–5450) 2580 (1460–4500) 2100
00 3520 (2130–5800) 2870 (1700–5340) 2340
.4. Probabilistic sensitivity analysis
Statistical uncertainty was assessed with multivariate
robabilistic sensitivity analysis using Monte Carlo simu-
ation with normal distributions for the parameters in both
egression models [21], with the means as specified in for-
ulas (1) and (2) and standard deviations derived from the
ame data (available on request). Monte Carlo simulation
hus enables specification of the uncertainty intervals for
ost-effectiveness (in particular, 10,000 simulations were per-
ormed to derive the 95% uncertainty interval using @RISK
.5 software).
. Results
The annual number of RSV-related hospitalisations in
utch children is estimated at 3670 (95% CI: 2160–6290),
osting on average D 14,170,400 per year (average costs per
ase: D 3860).
Hospital costs are estimated to account for the largest
urden of costs at D 12,328,200. Non-hospital costs due to
P-visits, work loss of parents and traveling fees amounted
p to approximately D 1,842,200.
The impact of the exact first month of protective immu-
ity on the number of cases of severe RSV-infections that
equire hospitalisation was assessed for a range of vaccine
ffectiveness from 50 to 100% and different first months of
rotection. The results are presented in Table 2. For 70%
ffectiveness, a vaccine that offers protective immunity to
nfants aged from 3 months onwards would decreases the






reak-even costs (D ) (vaccine price and administration costs) per vaccinated infan
onth of life (95% confidence intervals are shown between brackets)
ffectiveness (%) Start protective immunity (month of life)
1 2 3
50 34 (18–61) 26 (14–45) 21
60 41 (23–70) 32 (17–56) 25
70 47 (24–77) 37 (22–65) 29
80 54 (29–91) 42 (26–69) 33
90 61 (33–102) 47 (26–86) 38
00 68 (47–115) 53 (30–97) 423240) 1520 (880–2540) 1230 (670–2050) 990 (510–1960)
3560) 1710 (950–2860) 1380 (780–2560) 1110 (610–1960)
4030) 1900 (1080–3410) 1530 (850–2720) 1230 (670–2110)
ases per year. A vaccine with 90% effectiveness and pro-
ective immunity from 3 months onwards would result in
n annual decrease of approximately 2100 cases of RSV-
nfection.
An indication of the acceptable vaccine price for policy
akers could be made by calculation of the break-even costs
or vaccination (i.e. costs per vaccination so that the costs
f vaccination are fully offset by the financial benefits of
verting hospitalisation due to RSV). For a vaccine with a
0% effectiveness and protective immunity from month 3
nwards, these corresponding break-even costs would be D 29
95% CI: D 17–50). A vaccine with 90% effectiveness and
gain protective immunity from 3 months onwards would
ield break-even costs atD 38 (95% CI: 21–69). In Table 3, the
reak-even costs for the RSV-vaccine are shown as a function
f effectiveness and month of start of protection. One way
o interpret this Table is to consider one break-even price
say D 26 – and find those combinations of effectiveness
nd protective immunity that correspond to this price (in this
ase from 50% effectiveness and protective immunity from
months onwards up to 100% effectiveness and immunity
rom 5 months onwards).
As indicated above, RSV-infection follows a highly
easonal pattern, with most infections occurring between
ctober and April. As a result of this seasonality, vaccina-
ion of infants born in or just prior to the RSV-season would
ield optimal benefits. Thus, it could be worthwhile to only
accinate those infants born prior to the start of the RSV-
eason. This is shown in Fig. 3, which indicates the costs
er hospitalisation averted as a function of month of birth.
e have chosen here again for presenting results of a vac-
ine with 70% effectiveness and protective immunity from 3
t for a range of vaccine effectiveness and start of protective immunity by
4 5 6
(11–37) 17 (10–31) 13 (7–24) 11 (6–18)
(15–46) 20 (12–37) 16 (9–29) 13 (7–23)
(17–50) 23 (13–44) 18 (11–33) 15 (8–27)
(20–59) 27 (16–48) 21 (12–40) 17 (9–29)
(21–69) 30 (17–52) 24 (13–48) 19 (10–35)
(23–72) 33 (18–60) 26 (14–48) 21 (12–38)
J.M. Bos et al. / Vaccine 25
Fig. 3. Costs per hospitalisation due to RSV averted for infants born in
different months, for a vaccine with 70% effectiveness and protection from
3 months onwards and vaccination costs at D 26, with 95% CIs indicated by


















































































lre included; note that the exact values of these negative ratios may not
e meaningful; negatives merely show that we encounter the ‘desirable’
ituation of net cost savings combined with hospitalisations being averted).
onths onwards. For the vaccine costs we chose D 26, corre-
ponding to a theoretical one-dose vaccination with a vaccine
rice of D 20 plus administration costs of approximately D 6
r various subsequent vaccinations in the first months of life
t very low vaccine costs. The results are dependent on the
ime of birth of the infant in relation to the RSV-season. To
llustrate this, the costs per hospitalisation averted for infants
orn in January are approximately D 3400, whereas vaccina-
ion of infants born between June and September would be
ost-saving.
. Discussion & conclusion
In this analysis, we have calculated the impact of a
otential vaccine against RSV-infections for a number of
cenarios. One of the main purposes of this analysis was
o establish minimum values for both the effectiveness of
he vaccine and the timing of vaccination. Information on
hese crucial vaccine parameters could be used to drive strate-
ic research decisions with regard to the development of
uch a vaccine. For instance, a vaccine that needs to be
dministered shortly after or even prior to the partus would
equire a different research and development path than a more
onventional vaccine. Also, the analysis provides strategic
nformation for policy makers working on future develop-
ents of national vaccination programs in different countries.
t provides information on the possible public-health effects
f the intervention, as well as the associated costs of includ-
ng RSV-vaccination in a National Immunization Program.
his would enable policy makers to allocate budgets for such
vaccine upfront.
In the Netherlands, annually approximately 3670 hospi-
alisations in infants occur due to RSV-infection. Universal





mmunity in infants from 3 months onwards would avert
pproximately 1000–3000 hospitalisations, depending on the
ffectiveness of the vaccine. The break even price for vaccina-
ion would lie approximately between D 20 and 50, depending
gain on vaccine effectiveness. As an example, a vaccine that
ffers protective immunity to infants from the second month
f life onwards would prevent between 1430 and 2870 RSV-
ospitalisations, resulting in higher break-even costs for the
accination of between D 26 and D 53. Of course, the market
alue of such a vaccine is not only dictated by the break-even
rice of vaccination, also aspects such as willingness to pay
f parents or health-care authorities for prevention of RSV-
nfection among infants should be taken into consideration
nd may increase the prices as specified in this paper several
old. Additionally, we note that one further aspect for pricing
elates to the complexity of developing this vaccine and thus
he costs of the research and development necessary to bring
his vaccine to fruition; costs that are not included explicitly
n our analysis. Finally, we note that any potential downside
osts of vaccination, which might include medical visits if
he vaccine had febrile side effects and relevant costs of any
ore serious adverse effects, were not included in our model.
Break-even values most likely correspond with a one-
ff vaccination (instead of several subsequent doses), since
ecently introduced vaccines on average cost D 40 per dose
Mercer management consulting, personal communication).
lso, the results indicate that full protection would be needed
n infants as early as possible, which also points in the direc-
ion of a single shot vaccine given prior to the 2nd or 3rd
onth of life. In the absence of a fully characterized RSV-
accine, it is not yet clear whether this is technically feasible.
dditionally, we showed a variation in cost-effectiveness
egarding the seasonal timing of vaccination. This could
nduce a recommendation to vaccinate seasonally, for exam-
le, preferably prior to the RSV-season. However, given the
utch practice within the infant National Immunization Pro-
ram – which is of course universal rather than seasonal –
uch a seasonal vaccination might be difficult to implement,
lthough a successful example does exist for elderly seasonal
nfluenza vaccination.
Our model was limited to children without BPD. Inclusion
f children with BPD would have highly complicated our
ealth-economic model. Children with BPD only involve a
mall group (approximately 1% of all RSV-hospitalisations).
urthermore, one might expect that due to the relatively high
isk for severe RSV-disease in this group, less discussion on
accination for this small group might be expected, vaccina-
ion is highly likely to be cost saving and will only have a
ery limited budget impact.
This analysis of health effects of RSV-vaccination takes
nly hospitalisations due to RSV into account. However, a
arge number of RSV-infections in infants does not require
ospitalisation, and follows a similar clinical pathway as
ther respiratory illnesses (for example, as of influenza).
hese infections may cause significant burden for society due




























































[928 J.M. Bos et al. / Vac
n our analysis, the effects of vaccination on these milder
SV-infections are not incorporated, causing an underesti-
ation of the health effects of vaccination and the associated
reak-even costs for vaccination. Also, impacts in terms of
uality-of-life due to complications of RSV in later life (for
xample, wheezing) have not been evaluated in our current
ork; further work should be directed towards those impacts.
inally, we note that we did not find fatal cases of serious
SV-infections in our retrospective epidemiological research
16,17]. Thompson et al. did however estimated relevant mor-
ality due to RSV for the United States, using regression
odels on national mortality and respiratory virus surveil-
ance data [22]. This may indicate that further data gathering
n the Netherlands might also reveal relevant mortality due to
SV, and inclusion of this in the cost-effectiveness analysis
ay enhance cost-effectiveness of the potential vaccine.
If one would assume some modest mortality figures
n the range of 4–8 cases annually [22–24], some crude
ost-effectiveness estimates could be made. In particular,
hreshold vaccine costs could be estimated at which net
osts per life-year gained equal the informal Dutch cut-off
t D 20,000 per discounted life-year gained (discount rate at
.5% for life-years according to the Dutch guideline) [25,26].
or example, for a vaccine efficacy of 70% and protective
mmunity provided from the age of 3 months onwards, thresh-
ld vaccine costs would then range from D 50 to 75. Recently
igher cost-effectiveness thresholds have been suggested for
he Netherlands [27], allowing even much higher vaccina-
ion costs over D 100. Ergo, further research is needed into
he mortality of RSV among infants and its results would
rucially influence the exact levels of acceptable threshold
accination costs.
We conclude that in the Netherlands, annually approx-
mately 3670 hospitalisations in infants occur due to RSV
nfection. A vaccine could prevent a major share of these;
s early as possible vaccination after birth is crucial in this
espect. For breakeven, total vaccination costs related to
uch a vaccine would nevertheless not be allowed to be
ver approximately D 50. However, if further evidence on
ortality among infants with RSV would come out and war-
ant inclusion into a cost-effectiveness framework, indeed
ricing over D 50 upto above D 100 would become feasi-
le, based cost-effectiveness thresholds. With this model,
e demonstrate the potential value of health-economic mod-
lling to assist in R&D-decisions, in this case enabling
ational weighting of the benefits and pricing of vaccination
ersus R&D-investments required.
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